LTGO Latigo Biotherapeutics, Inc. - Common Stock
No fundamentals data yet for this ticker.
Company insiders 3 insiders · 0 officers · 0 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| James B. Tananbaum | — | Aug. 10, 2026 C | 3,414,544 | 1 | 0 | $2,520,000 |
| Beth C Seidenberg | — | Aug. 10, 2026 C | 2,094,813 | 0 | 0 | $0 |
| Todd N Smith | — | Aug. 6, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC, Foresite Capital Fund V, L.P., Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC, James B. Tananbaum | Aug. 17, 2026 | 14.50% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.